Tafolecimab (PCSK9) Antibody, Monoclonal | 11-001

Tafolecimab (PCSK9) Antibody, Monoclonal | 11-001 | Gentaur UK, US & Europe Distribution

Host: N/A

Reactivity: N/A

Homology: N/A

Immunogen: Homo sapiens / PCSK9 [Homo sapiens]

Research Area: Drug Analogues

Tested Application: N/A

Application: N/A

Specificiy: N/A

Positive Control 1: N/A

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: N/A

Validation: N/A

Isoform: N/A

Purification: >95%

Clonality: Monoclonal

Clone: N/A

Isotype: IgG2-kappa

Conjugate: Unconjugated

Physical State: N/A

Buffer: PBS buffer pH7.5

Concentration: N/A

Storage Condition: Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 ˚C for 1-2 weeks. Store at -20 ˚C for 12 months. Store at -80 ˚C for long term storage.

Alternate Name: IBI-306

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: GPRC5D / CD3 bispecific antibody is used to treat multiple myeloma. The bispecific antibody is commonly known as tafolecimab. It is constructed using the Duobody technology authorized by Genmab. The heavy chain of anti-CD3 antibody introduced F405L and R409K to construct the double antibody. S228P, F234A, and L235A mutations were simultaneously introduced into the IgG4 constant region.